Article Text
Review
Contraception choice for HIV positive women
Abstract
UNAIDS/WHO estimates that 42 million people are living with HIV/AIDS worldwide and 50% of all adults with HIV infection are women predominantly infected via heterosexual transmission. Women with HIV infection, like other women, may wish to plan pregnancy, limit their family, or avoid pregnancy. Health professionals should enable these reproductive choices by counselling and appropriate contraception provision at the time of HIV diagnosis and during follow up. The aim of this article is to present a global overview of contraception choice for women living with HIV infection including effects on sexual transmission risk.
- contraception
- HIV
- women
- COC, combined contraceptive pill
- DMPA, depot medroxyprogesterone acetate
- HAART, highly active antiretroviral therapy
- IUDs, intrauterine devices
- LNG-IUS, levonorgestrel intrauterine system
- NET-EN, norethisterone enanthate
- NNRTIs, non-nucleotide reverse transcriptase inhibitors
- PID, pelvic inflammatory disease
- PIs, protease inhibitors
- POP, progestogen only pill
Statistics from Altmetric.com
- COC, combined contraceptive pill
- DMPA, depot medroxyprogesterone acetate
- HAART, highly active antiretroviral therapy
- IUDs, intrauterine devices
- LNG-IUS, levonorgestrel intrauterine system
- NET-EN, norethisterone enanthate
- NNRTIs, non-nucleotide reverse transcriptase inhibitors
- PID, pelvic inflammatory disease
- PIs, protease inhibitors
- POP, progestogen only pill
Footnotes
Linked Articles
- Brief Encounters